Apria (APR) Peer Comparison
$37.50
$0.00 (0.00%)As on 07-Apr-2022 09:30EDT
Market cap
$1,340 Mln
Revenue (TTM)
$1,145 Mln
P/E Ratio
22.6
P/B Ratio
33.7
Div. Yield
0 %
Edit
| Apria (APR) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1,340 | 12,753 | 12,153 | 10,906 | 9,762 |
Revenue ($ Mln) |
1,145 | 1,505 | 6,164 | 613 | 2,589 |
Net Profit ($ Mln) |
64.88 | 160.59 | 625.00 | -188.05 | 222.40 |
Net Margin (%) |
5.67 | 10.67 | 5.41 | -30.68 | 8.59 |
RoE (%) |
969.18 | 10.86 | 11.84 | -28.10 | 3.04 |
Price to Earnings |
22.59 | 79.35 | 19.89 | -- | 44.47 |
Price-To-Book |
33.73 | 8.41 | 2.37 | 16.38 | 1.26 |
Income Statement ($ Mln)
| Apria (APR) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,145.28 | 747.59 | 5,212.00 | 294.01 | 2,922.55 |
|
Cost of Revenue
|
341.29 | 272.21 | 1,514.00 | 66.63 | 1,284.45 |
|
Gross Profit
|
803.99 | 475.38 | 3,698.00 | 227.38 | 1,638.10 |
|
Operating Expenses
|
706.63 | 482.88 | 3,105.00 | 260.26 | 1,137.76 |
|
Operating Profit (EBIT)
|
97.35 | -7.50 | 593.00 | -32.87 | 500.34 |
|
Other Income
|
-0.54 | -3.94 | -- | 1.29 | 24.02 |
|
Profit before Tax
|
89.82 | -10.50 | 586.00 | -49.27 | 5,449.06 |
|
Provision for Tax
|
24.15 | -13.13 | 62.00 | 0.33 | 1,194.80 |
|
Profit after Tax (Net Income)
|
64.88 | 2.62 | 524.00 | -49.59 | 4,254.26 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
64.88 | 5.28 | 524.00 | -49.59 | 4,245.90 |
Liabilities ($ Mln)
| Apria (APR) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
39.73 | 953.93 | 5,568.00 | 587.15 | 13,685.24 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
428.87 | 167.13 | 3,221.00 | 478.32 | 3,433.22 |
|
Current Liabilities
|
306.83 | 123.20 | 2,131.00 | 63.36 | 680.94 |
|
Total Liabilities
|
775.43 | 1,244.25 | 10,920.00 | 1,128.83 | 17,799.39 |
Assets ($ Mln)
| Apria (APR) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
442.15 | 562.78 | 6,496.00 | 642.70 | 15,808.83 |
|
Current Assets
|
333.28 | 681.47 | 4,424.00 | 486.13 | 1,990.48 |
|
Total Assets
|
775.43 | 1,244.25 | 10,920.00 | 1,128.83 | 17,799.39 |
|
Total Debt*
|
449.18 | 173.55 | 3,339.00 | 383.39 | 223.38 |
|
Net Current Assets
|
26.45 | 558.28 | 2,293.00 | 422.77 | 1,308.15 |
Cashflow ($ Mln)
| Apria (APR) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
212.00 | 9.50 | 877.00 | 24.71 | 669.46 |
|
Cash Flow from Investing Activities
|
-144.21 | -21.74 | -691.00 | -58.23 | -797.38 |
|
Cash from Financing Activities
|
-42.91 | 0.84 | -645.00 | 39.26 | -55.43 |
|
Net Cash Inflow / Outflow
|
24.88 | -11.40 | -- | 3.96 | -195.98 |
Ratios
Profitability Ratios
| Apria (APR) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
14.68 | 0.28 | 5.86 | -5.19 | 35.43 |
|
ROE (%)
|
969.18 | 0.33 | 9.66 | -7.91 | 36.11 |
|
ROA (%)
|
8.76 | 0.25 | 4.78 | -4.65 | 27.65 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
5.67 | 0.35 | 10.05 | -16.79 | 144.38 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Apria (APR) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.03 | 0.33 | 0.14 | 0.31 | 0.15 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
40.61 | 113.62 | 16.96 | 58.79 | 11.54 |
|
EPS Growth (%)
|
-- | 1.14 | 0.17 | 0.60 | 0.12 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Apria (APR) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
19.09 | 4,102.34 | 58.00 | -42.05 | 5.08 |
|
Price / Book Value
|
31.18 | 11.28 | 5.46 | 3.55 | 1.58 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
6.80 | 1,198.96 | 26.76 | -1,393.86 | 3.76 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Apria (APR) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
11.31 | 0.18 | 0.60 | 0.65 | 0.02 |
|
Short term debt to equity ratio
|
1.51 | 0.01 | 0.09 | 0.00 | 0.00 |
|
Current Ratio
|
1.09 | 5.53 | 2.08 | 7.67 | 2.92 |
|
Quick Ratio
|
1.06 | 3.39 | 1.21 | 7.31 | 2.08 |
|
Interest Coverage
|
-- | -0.47 | 8.90 | -2.68 | 3,514.25 |
Operating Efficiency Ratios
| Apria (APR) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
7.14 | 17.92 | 18.63 | 11.37 | 14.49 |
|
Asset Turnover
|
1.55 | 0.72 | 0.48 | 0.28 | 0.19 |
|
Receivable days
|
24.95 | 60.72 | 65.94 | 43.17 | 52.68 |
|
Inventory Days
|
8.26 | 324.07 | 426.41 | 106.41 | 169.83 |
|
Payable days
|
133.97 | 18.47 | 233.29 | 32.08 | 40.01 |
|
Cash Conversion Cycle
|
-100.76 | 366.31 | 259.06 | 117.49 | 182.50 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
